Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FBXO3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FBXO3 Recombinant Protein (WT/APA Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 expressed. |
View FBXO3 Products |
| Gene Delivery | FBXO3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View FBXO3 Products |
| Benchmark Ab | Anti-FBXO3 Antibody Recombinant positive control for Western Blot, ELISA, and IP. |
View FBXO3 Products |
| Validator | FBXO3 siRNA Set For knockdown verification and specificity controls. |
View FBXO3 Products |
| Related Target A | FBXL2 Direct physiological substrate of FBXO3; degradation of FBXL2 triggers inflammatory cascades. |
View FBXL2 Products |
| Related Target B | SKP1 Essential adapter protein of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex. |
View SKP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting E3 ligase ubiquitination cascade in vitro | High-purity recombinant FBXO3, SKP1, and substrate proteins strictly verified by SDS-PAGE and Mass Spectrometry. |
| Screening for small-molecule inhibitors blocking FBXO3-FBXL2 interaction | Truncated FBXO3 (APA domain) and FBXL2 proteins optimized for high-sensitivity SPR and AlphaLISA assays. |
| Lack of Controls | Sequence-verified benchmark antibodies and positive control expression plasmids included. |
| False Positives | Validated siRNA pools included for target-specific knockdown and orthologous validation. |
Live FBXO3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FBXO3 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum anti-inflammatories to targeted E3 ligase inhibitors. FBXO3 acts as a key upstream regulator of inflammatory cytokine storms by degrading the anti-inflammatory protein FBXL2. As first-generation small-molecule inhibitors (such as BC-1215 derivatives) reach preclinical validation, the next wave of R&D is targeting the specific APA domain of FBXO3 to prevent off-target E3 ligase toxicity and achieve highly selective therapeutic indexes in acute lung injury, COPD, and cytokine release syndrome.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | University of Pittsburgh, Enterin | Sepsis, COPD, Acute Lung Injury (ALI) | In vitro binding assays (Need high-purity FBXO3 APA domain & FBXL2 proteins) |
| PROTAC / Molecular Glues | Academic & Biotech Consortia | Oncology, Inflammatory Disorders | Ternary complex formation assays (Need SKP1-Cullin-FBXO3 complex verification) |